Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G-protein coupled receptor 146 (GPR146) is a class A orphan G-protein coupled receptor that has recently emerged as a critical regulator of systemic lipid and cholesterol homeostasis. It is highly expressed in metabolically active tissues, particularly the liver and adipose tissue, where it modulates hepatic lipoprotein secretion and de novo cholesterol biosynthesis. Mechanistically, GPR146 promotes the activity of hepatic sterol regulatory element-binding protein 2 (SREBP2) via the extracellular signal-regulated kinase (ERK) pathway, thereby regulating very low-density lipoprotein (VLDL) secretion and circulating low-density lipoprotein cholesterol (LDL-C) levels. Recently, the gut-derived hormone cholesin was identified as an endogenous ligand for GPR146; cholesin binding to GPR146 inhibits hepatic cholesterol synthesis, linking intestinal cholesterol absorption to hepatic de novo synthesis.\n\nIn terms of disease pathology, genetic variants near the GPR146 locus (such as rs1997243) are strongly associated with elevated plasma cholesterol levels and increased risk of cardiovascular disease in humans. Conversely, GPR146 deficiency or knockout in animal models significantly reduces circulating cholesterol and triglycerides, and protects against atherosclerotic plaque formation, making it an attractive therapeutic target for hypercholesterolemia and atherosclerosis. Beyond cardiovascular disease, GPR146 has been implicated in pulmonary hypertension, vascular remodeling, and immune-inflammatory responses. Therapeutic strategies currently under exploration include GPR146 antagonists, neutralizing antibodies, and siRNA-mediated knockdown to lower lipid levels, as well as the administration of cholesin or cholesin mimetics to suppress cholesterol synthesis.
GPR146 antagonism or inhibition (e.g., via neutralizing antibodies, siRNA, or small-molecule antagonists) to lower plasma cholesterol and reduce atherosclerosis, or GPR146 activation/agonism by its endogenous ligand Cholesin to suppress hepatic cholesterol synthesis.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G-protein coupled receptor 146 (GPR146).